

## **Clobazam/vigabatrin/IV carbamazepine**

Ovation Pharmaceuticals, Inc. will present an update on the development programs for two of its anticonvulsants, clobazam and intravenous carbamazepine. Clobazam is currently in a Phase 3 study, in the United States, Europe and Australia for the treatment of drop seizures in Lennox-Gastaut Syndrome. In the Phase 2 study conducted by Ovation, clobazam achieved an 85% reduction in drop seizures with an average dose of 1mg/kg, and demonstrated very good tolerability at that dose. Nearly all (63/68) subjects elected to continue on clobazam in the extension phase of the study, with continuing evidence of effectiveness against drop seizures.

Intravenous carbamazepine is being developed as a replacement therapy in those patients taking carbamazepine for epilepsy who are temporarily unable to tolerate oral therapy. A multi-center study of the pharmacokinetics and safety of various doses of this first and only injectable form of carbamazepine has already dosed 77 subjects, and is scheduled for completion later this year.